跳至主要内容
临床试验/JPRN-UMIN000014269
JPRN-UMIN000014269已完成未知

Concurrent use of Sr-89 chloride with bone-modifying agent(denosumab, zoledronic acid) is safe and effective for breast cancer patients with painful bone metastases - Concurrent use of Sr-89 chloride with bone-modifying agent is safe and effective for breast cancer patients with painful bone metastases

St. Marianna University School of Medicine0 个研究点目标入组 15 人开始时间: 2014年6月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 ot applicable(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. a case indicated chemotherapy 2. a case that has other cancer 3. a case that has grave complication 4. a case that has grave bone marrow suppression 5. a case that has grave renal dysfunction 6. a case that has invasive dental treatment 7. a woman that is pregnant, breast-feed and may be pregnant

研究者

相似试验